BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1933871)

  • 1. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.
    Adamson PC; Balis FM; Arndt CA; Holcenberg JS; Narang PK; Murphy RF; Gillespie AJ; Poplack DG
    Cancer Res; 1991 Nov; 51(22):6079-83. PubMed ID: 1933871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
    Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
    J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
    Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
    Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
    Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
    Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
    J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
    Estlin EJ
    Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion.
    Zimm S; Ettinger LJ; Holcenberg JS; Kamen BA; Vietti TJ; Belasco J; Cogliano-Shutta N; Balis F; Lavi LE; Collins JM
    Cancer Res; 1985 Apr; 45(4):1869-73. PubMed ID: 4038917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia.
    Zimm S; Reaman G; Murphy RF; Poplack DG
    Cancer Res; 1986 Mar; 46(3):1495-8. PubMed ID: 2417705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
    Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
    Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic approaches to the treatment of meningeal malignancy.
    Blaney SM; Balis FM; Poplack DG
    Oncology (Williston Park); 1991 May; 5(5):107-16; discussion 123, 127. PubMed ID: 1831994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
    Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
    Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
    Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
    Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.